小白菊作为偏头痛的预防性治疗：一项系统评价。
Feverfew as a preventive treatment for migraine: a systematic review.
作者信息
Vogler B K, Pittler M H, Ernst E
机构信息
Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter, UK.
出版信息
Cephalalgia. 1998 Dec;18(10):704-8. doi: 10.1046/j.1468-2982.1998.1810704.x.
BACKGROUND
Feverfew is a popular herbal remedy advocated for the prevention of migraine.
AIM
The aim of this systematic review was to look at the evidence for or against the clinical effectiveness of feverfew in migraine prevention.
DATA SOURCES
Literature searches were performed using the following databases: Medline, Embase, Biosis, CISCOM, and the Cochrane Library (all from their inception to April 1998).
STUDY SELECTION
Only randomized, placebo-controlled, double-blind trials were included.
DATA EXTRACTION
All articles were read by two independent reviewers. Data were extracted in a predefined, standardized fashion. The methodological quality of all trials was evaluated using the Jadad score.
MAIN RESULTS
Five trials met the inclusion/exclusion criteria. The majority favor feverfew over placebo. Yet important caveats exist.
CONCLUSION
The clinical effectiveness of feverfew in the prevention of migraine has not been established beyond reasonable doubt.
背景
小白菊是一种常用的草药疗法，被提倡用于预防偏头痛。
目的
本系统评价的目的是研究支持或反对小白菊预防偏头痛临床有效性的证据。
数据来源
使用以下数据库进行文献检索：医学索引数据库（Medline）、荷兰医学文摘数据库（Embase）、生物学文摘数据库（Biosis）、补充医学数据库（CISCOM）和考克兰图书馆（均从其创建至1998年4月）。
研究选择
仅纳入随机、安慰剂对照、双盲试验。
数据提取
所有文章由两名独立的评审员阅读。数据以预定义的标准化方式提取。使用雅达评分评估所有试验的方法学质量。
主要结果
五项试验符合纳入/排除标准。大多数试验表明小白菊优于安慰剂。然而，存在重要的注意事项。
结论
小白菊预防偏头痛的临床有效性尚未得到确凿证实。
Zotero 插件